A Phase 2 interventional study of PM8002 and FOLFOX regimen in Hepatocellular Carcinoma, sponsored by Biotheus Inc.. Completed at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.
Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 741st largest by enrollment of the 1,034 interventional ones that give a count, is one of 111 that started in 2022, is one of 331 in phase 2, and was the 818th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Sites in China
Ages 18+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Anhui Provincial Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,310 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 227 · Phase 2 454 · Phase 3 203 · Phase 4 38
First in 1983; this study’s year is marked. 111 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 78 across the 1,034 interventional studies, 300 across the 275 observational. Of the 327 that completed or were terminated, 49 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
235 of 1,310 have an industry lead sponsor. The 10 most frequent:
This study is registered under Biotheus Inc., one of the names counted as BioNTech SE. Under that name alone:
Biotheus Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.
BioNTech SE has 1 study filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
131 of the studies in Carcinoma, Hepatocellular with a site in China that are under way reach primary completion within a year, 15 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03368651Phase 3Sun Yat-sen UniversityThe Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial. | 2026-11-30 |
| NCT04344158Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | 2026-12 |
| NCT05062837Phase 3Guangxi Medical UniversityHepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | 2026-12-30 |
| NCT03859128Phase 3Shanghai Junshi Bioscience Co., Ltd.Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection | 2026-12-31 |
| NCT04523493Phase 3Shanghai Junshi Bioscience Co., Ltd.Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCC | 2026-12-31 |
Add all 131 to your calendar (.ics) → With an account.
Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.
PM8002 is a Bispecific Antibody Targeting PD-L1 and VEGF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PM8002 20mg/kg Q2W day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
Biological: PM8002 · Drug: FOLFOX regimen
PM8002 20mg/kg Q2W
day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
Objective Response Rate
Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.
Time frame: Up to approximately 2 years
Plan to share: Yes — The data will be published or presented for publications (poster, abstract, articles or papers) or any presentations.
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Jul 2025, 39 months.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 39 months is close to that.
Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pumitamig